Ventolin diskus and inspyril turbuhaler: An in vitro comparison

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 18, Issue 1, 2005, Pages 74-82

  Broeders, M E A C ^a   Molema, J ^a   Burnell, P K P ^b   Folgering, H T M ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Glaxo Smith Kline   (United Kingdom)

Author keywords

Diskus; Dry powder inhaler; Electronic lung; Fine particle mass; Turbuhaler

Indexed keywords

SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRY POWDER; FEMALE; HOSPITALIZATION; HUMAN; INHALATION; INHALER; MALE; OUTPATIENT; PARAMETER; PARTICLE SIZE; RESPIRATORY AIRFLOW; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ASTHMA; COMPUTER SIMULATION; EQUIPMENT DESIGN; FEMALE; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 14844331714     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2005.18.74     Document Type: Article

References (27)

1. Pauwels, R., Newman, S., and Borgstrom, L. 1997. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Respir. J. 10:2127-2138.
2. Dolovich, M.A. 2000. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir. Care 45:597-608.
3. Clark, A.R., and Hollingworth, A.M. 1993. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J. Aerosol Med. 1993;6:99-110.
4. Hawksworth, G.M., James, L., and Chrystyn, H. 2000. Characterization of the inspiratory manoeuvre when astmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy. Respir. Med. 94:501-504.
5. Everard, M.L., Devadason, S.G., and Le Souef, P.N. 1997. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 91:624-628.
6. de Boer, A.H., Winter, H.M.I., and Lerk, C.F. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int. J. Pharm. 130:231-244.
7. Carveth, H.C., and Kanner, R.E. 1999. Optimizing deposition of aerosolized drug in the lung: a review. Medscape Respir. Care 3.
8. de Boer, A.H., Gjaltema, D., and Hagedoorn, P. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138:45-56.
9. Sciarra, J. 1966. International Encyclopaedia of Pressurized Packaging (Aerosols). Pergamon Press, New York.
10. Burnell, P.K.P., Malton, A., Reavill, K., et al. 1998. Design, validation and initial testing of the electronic lung device. J. Aerosol Sci. 29:1011-1025.
11. Bisgaard, H., Klug, B., Sumby, B.S., et al. 1998. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 11:1111-1115.
12. Broeders, M.E., Molema, J., Hop, W.C., et al. 2003. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J. Aerosol Med. 16:131-141.
13. Broeders, M.E., Molema, J., and Folgering, H.T. 2002. Do asthma and COPD patients adequately inhale their medication during acute exacerbation. Am. J. Respir. Crit. Care Med. 165:B7.
14. Brindley, A., Sumby, B.S., and Smith, I.J. 1994. The characterisation of inhalation devices by an inhalation simulator: the electronic lung. J. Aerosol Med. 7:197-200.
15. Broeders, M.E., Molema, J., and Folgering, H.T. 2001. Resistivities of placebo and active Diskus inhalers compared. Int. J. Pharm. 228:219-222.
16. Burnell, P.K., Malton, A., Reavill, K., et al. 1998. Design, validation and initial testing of the electronic lung device. J. Aerosol Sci. 29:1011-1025.
17. Chavan, V., and Dalby, R. 2000. Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers. AAPS Pharm. Sci. 2:E10.
18. de Koning, J.P., van der Mark, T.W., Coenegracht, P.M.J., et al. 2002. Effect of an external resistance to airflow on the inspiratory flow curve. Int. J. Pharm. 234:257-266.
19. Fuller, R. 1995, The Diskus: a new multi-dose powder device - efficacy and comparison with Turbuhaler. J. Aerosol Med. 8(Suppl 2):S11-S17.
20. Davies, N., Feddah, M., Brown, K., et al. 2000. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J. Pharm Pharmac. Sci. 3:317-324.
21. Hill, L.S., and Slater, A.L. 1998. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir. Med. 92:105-110.
22. Malton, A., Sumby, B.S., and Smith, I.J. 1995. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur. J. Clin. Res. 7:177-193.
23. Prime, D., Grant, A.C., Slater, A.L., et al. 1999. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J. Aerosol Med. 12:75-84.
24. Kamin, W.E., Genz, T., Roeder, S., et al. 2002. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol. Med. 15:65-73.
25. Burnell, P.K., Small, T., Doig, S., et al. 2001. Ex vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir. Med. 95:324-330.
26. de Boer, A.H., Bolhuis, G.K., Gjaltema, D., et al. 1997. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 3. The effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler. Int. J. Pharm. 153:67-77.
27. Broeders, M.E., Molema, J., Vermue, N.A., et al. 2001. Peak Inspiratory Flow Rate and slope of the inhalation profiles in Dry Powder Inhalers. Eur. Respir. J. 780-783.